Granted Patent
B2
US 12,239,732 · App. 17/814,728 · Granted Mar 4, 2025
Anti-CD37 immunoconjugate and anti-CD20 antibody combinations
Inventors:
Angela Romanelli (Lexington, MA); Rodrigo R. Ruiz-Soto (Boston, MA); Jose Ponte (Weymouth, MA); Jutta Deckert (Lexington, MA); Jan Pinkas (Belmont, MA)
Assignee:
DEBIOPHARM INTERNATIONAL, S.A.
A61K9/0019A61K47/6801A61K47/68033A61K47/6849A61K47/6867A61P35/02C07K16/2887C07K16/2896A61K2039/507A61K2039/545C07K2317/24
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods of administering immunoconjugates that bind to CD37 (e.g., IMGN529) in combination with antibodies that bind to CD20 are provided. The methods comprise administering an anti-CD37 immunoconjugate (e.g., IMGN529) and an anti-CD20 antibody to a person in need thereof, for example, a cancer patient.
Claims (12)
1. A method for treating a human patient having a B-cell cancer comprising administering to said patient in need thereof (i) an immunoconjugate that binds to CD37 comprising a DM1 maytansinoid, a linker, and an antibody that binds to CD37 comprising the variable heavy chain sequence set forth in SEQ ID NO: 12 and the variable light chain sequence set forth in SEQ ID NO: 15; and (ii) rituximab, wherein said immunoconjugate that binds to CD37 is administered at a dose of 0.7 mg/kg once every three weeks and wherein the rituximab is administered at a dose of about 375 mg/m 2 on week 1, day 1 of a three week schedule.
2. The method of claim 1 , wherein the immunoconjugate that binds to CD37 and the rituximab produce a synergistic effect, with a Synergy Score of at least 4 in vitro.
3. The method of claim 1 , wherein the immunoconjugate that binds to CD37 and the rituximab have a combination index value of less than 0.5.
4. The method of claim 1 , wherein the cancer is leukemia or lymphoma.
5. The method of claim 1 , wherein the cancer is selected from the group consisting of NHL, precursor B-cell lymphoblastic leukemia/lymphoma, B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, mantle cell lymphoma (MCL), follicular lymphoma (FL), cutaneous follicle center lymphoma, marginal zone B-cell lymphoma, hairy cell leukemia, diffuse large B-cell lymphoma (DLBCL), Burkitt's lymphoma, plasmacytoma, plasma cell myeloma, post-transplant lymphoproliferative disorder, Waldenstrom's macroglobulinemia, acute lymphoblastic leukemia (ALL), and anaplastic large-cell lymphoma (ALCL).
6. The method of claim 5 , wherein the cancer is NHL.
7. The method of claim 6 , wherein the NHL is relapsed or refractory NHL.
8. The method of claim 1 , wherein the cancer overexpresses MYC and/or BCL2.
9. The method of claim 1 , wherein the immunoconjugate that binds to CD37 and the rituximab are administered intravenously.
10. The method of claim 1 further comprising administering a growth factor to the patient.
11. The method of claim 1 , wherein the human patient has relapsed diffuse large B-cell lymphoma (DLBCL).
12. The method of claim 1 , wherein the antibody that binds to CD37 comprises the heavy chain sequence set forth in SEQ ID NO: 18 and the light chain sequence set forth in SEQ ID NO: 21.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 6, 2023
From: IMMUNOGEN, INC.
To: DEBIOPHARM INTERNATIONAL, S.A.
Reel/Frame 062303/0536 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 6, 2023
From: ROMANELLI, ANGELA; RUIZ-SOTO, RODRIGO R.; PONTE, JOSE; DECKERT, JUTTA; PINKAS, JAN
To: IMMUNOGEN, INC.
Reel/Frame 062303/0585 →
Continuity (5)
Provisional Application
62263449
· Dec 4, 2015
Provisional Application
62172672
· Jun 8, 2015
References Cited (283)
US 5122368A
· Greenfield et al.
· 1992
[cited by applicant]
US 5595756A
· Bally
· 1997
[cited by applicant]
US 7303749B1
· Chari
· 2007
[cited by applicant]
US 7585491B2
· Govindan
· 2009
[cited by applicant]
US 7601354B2
· Chari
· 2009
[cited by applicant]
US 7989598B2
· Steeves et al.
· 2011
[cited by applicant]
US 8088387B2
· Steeves et al.
· 2012
[cited by applicant]
US 8765917B2
· Deckert et al.
· 2014
[cited by applicant]
US 9346887B2
· Deckert et al.
· 2016
[cited by applicant]
US 9447189B2
· Deckert et al.
· 2016
[cited by applicant]
US 20030114398A1
· Chatterjee et al.
· 2003
[cited by applicant]
US 20040166115A1
· Griffiths et al.
· 2004
[cited by applicant]
US 20070009519A1
· Hariharan et al.
· 2007
[cited by applicant]
US 20080226626A1
· Hariharan et al.
· 2008
[cited by applicant]
US 20080227198A1
· Hariharan et al.
· 2008
[cited by applicant]
US 20080279850A1
· Brady et al.
· 2008
[cited by applicant]
US 20090041783A1
· Takayama et al.
· 2009
[cited by applicant]
US 20090148447A1
· Ledbetter et al.
· 2009
[cited by applicant]
US 20090175867A1
· Thompson et al.
· 2009
[cited by applicant]
US 20100135900A1
· Cerveny et al.
· 2010
[cited by applicant]
US 20100189722A1
· Heider et al.
· 2010
[cited by applicant]
US 20120020983A9
· Braun
· 2012
[cited by applicant]
US 20130058947A1
· Stull et al.
· 2013
[cited by applicant]
US 20140120083A1
· Stern et al.
· 2014
[cited by applicant]
US 20140348745A1
· Larsen et al.
· 2014
[cited by applicant]
US 20150093397A1
· Carrigan
· 2015
[cited by applicant]
US 20150343077A1
· Deckert et al.
· 2015
[cited by applicant]
US 20170000900A1
· Romanelli
· 2017
[cited by applicant]
US 20200270361A1
· Deckert et al.
· 2020
[cited by applicant]
CN 1446104A
· 2003
[cited by applicant]
CN 1494433A
· 2004
[cited by applicant]
CN 1568198A
· 2005
[cited by applicant]
EP 0328147B1
· 1994
[cited by applicant]
JP 2006513203A
· 2006
[cited by applicant]
JP 2013524777A
· 2013
[cited by applicant]
JP 2016536298A
· 2016
[cited by applicant]
WO WO0124763A2
· 2001
[cited by applicant]
WO WO0204021A1
· 2002
[cited by applicant]
WO WO02060484A1
· 2002
[cited by applicant]
WO WO02060485A2
· 2002
[cited by applicant]
WO WO2002102972A2
· 2002
[cited by applicant]
WO WO03048306A2
· 2003
[cited by applicant]
WO WO03083069A2
· 2003
[cited by applicant]
WO WO2004058298A1
· 2004
[cited by applicant]
WO WO2005017148A1
· 2005
[cited by applicant]
WO WO2005037989A2
· 2005
[cited by applicant]
WO WO2005037992A2
· 2005
[cited by applicant]
WO WO2006074397A2
· 2006
[cited by applicant]
WO WO2006133450A2
· 2006
[cited by applicant]
WO WO2007014278A2
· 2007
[cited by applicant]
WO WO2007077173A1
· 2007
[cited by applicant]
WO WO2007146968A2
· 2007
[cited by applicant]
WO WO2007140371A2
· 2007
[cited by applicant]
WO WO2008052030A2
· 2008
[cited by applicant]
WO WO2008119567A2
· 2008
[cited by applicant]
WO WO2009019312A2
· 2009
[cited by applicant]
WO WO2009065576A1
· 2009
[cited by applicant]
WO WO2009085576A2
· 2009
[cited by applicant]
WO WO2009126858A2
· 2009
[cited by applicant]
WO WO2009126944A1
· 2009
[cited by applicant]
WO WO2009134977A1
· 2009
[cited by applicant]
WO WO2010008726A1
· 2010
[cited by applicant]
WO WO2010009124A2
· 2010
[cited by applicant]
WO WO2010126551A1
· 2010
[cited by applicant]
WO WO2011090754A1
· 2011
[cited by applicant]
WO WO2011090762A1
· 2011
[cited by applicant]
WO WO2011100398A1
· 2011
[cited by applicant]
WO WO2011100403A1
· 2011
[cited by applicant]
WO WO2011112978A1
· 2011
[cited by applicant]
WO WO2012135740A2
· 2012
[cited by applicant]
WO WO2013149171A2
· 2013
[cited by applicant]
WO WO2013171289A1
· 2013
[cited by applicant]
WO WO2014143807A2
· 2014
[cited by applicant]
WO WO2014195460A1
· 2014
[cited by applicant]
WO WO2014197411A1
· 2014
[cited by applicant]
WO WO2015038777A1
· 2015
[cited by applicant]
WO WO2015067586A2
· 2015
[cited by applicant]
WO WO2015116729A2
· 2015
[cited by applicant]
WO WO2015175533A2
· 2015
[cited by applicant]
WO WO2016200676A1
· 2016
[cited by applicant]
WO WO2017040247A1
· 2017
[cited by applicant]
WO WO2018083633A1
· 2018
[cited by applicant]
WO WO2019229677A1
· 2019
[cited by applicant]
Smith et al., Blood Cells, Molecules, and Diseases, 2010, 45:317-323 (Year: 2010).
[cited by examiner]
Angelisová, P., et al., “Association of four antigens of the tetraspans family (CD37, CD53, TAPA-1, and R2/C33) with MHC class II glycoproteins,”
[cited by applicant]
Bernstein, I.D., et al., “High Dose Radiolabeled Antibody Therapy of Lymphoma,”
[cited by applicant]
Braslawsky, G.R., et al., “Antitumor Activity of Adriamycin (Hydrazone-linked) Immunoconjugates Compared with Free Adriamycin and Specificity of Tumor Cell Killing,”
[cited by applicant]
Deckert, J., et al., “IMGN529: A therapeutic maytansinoid conjugate of an anti-CD37 antibody with multiple mechanisms of action for B-cell lymphoma and leukemia,” AACR Poster Abstract #2, Apr. 2-6, 2011.
[cited by applicant]
Deckert, J., et al., “IMGN529: An Anti-CD37 Antibody-Maytansinoid Conjugate with Multiple Mechanisms of Actions for B-Cell Malignancies,” Poster #306,
[cited by applicant]
Deckert, J., et al., “Potent B-Cell Depletion by IMGN529, a CD37-Targeting Antibody-Maytansinoid Conjugate for the Treatment of B-Cell Malignancies,” ASH Poster Abstract #3726:1-2 (2011).
[cited by applicant]
Dijoseph, J.F., et al. “CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab,”
[cited by applicant]
Greenfield, R.S., et al., “Evaluation in Vitro of Adriamycin Immunoconjugates Synthesized Using an Acid-sensitive Hydrazone Linker,”
[cited by applicant]
International Search Report with Written Opinion for International Application No. PCT/US11/28172, International Searching Authority, United States, mailed Jul. 13, 2011.
[cited by applicant]
Kaminski, M.S., et al. “Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma,”
[cited by applicant]
Knobeloch, K-P., et al., “Targeted Inactivation of the Tetraspanin CD37 Impairs T-Cell-Dependent B-Cell Response under Suboptimal Costimulatory Conditions,”
[cited by applicant]
Lai, K.C., et al., “The CD37-targeting ADC IMGN529 combines the potent anti-cancer activity of K7153A antibody with efficient maytansinoid delivery,” Poster Abstract #B209,
[cited by applicant]
Lai, K.C., et al., “The CD37-targeting ADC IMGN529 combines the potent anti-cancer activity of K7153A antibody with efficient maytansinoid delivery,”
[cited by applicant]
Link, M.P., et al., “A Unique Antigen on Mature B Cells Defined by a Monoclonal Antibody,”
[cited by applicant]
Maecker, H.T., et al., “The tetraspanin superfamily: molecular facilitators,”
[cited by applicant]
Meyer-Wentrup, F., et al., “Dectin-1 Interaction with Tetraspanin CD37 Inhibits IL-6 Production,”
[cited by applicant]
Moore, K., et al., “Use of the Monoclonal Antibody WR17, Identifying the CD37 gp40-45 Kd Antigen Complex, in the Diagnosis of B-Lymphoid Malignancy,”
[cited by applicant]
Park, P.U., et al., “Antibody and linker selection for the anti-CD37 antibody-maytansinoid conjugate IMGN529 for the treatment of B-cell malignancies,”
[cited by applicant]
Pinkas, J., “Antibody Maytansinoid Conjugates for the Treatment of Cancer,” Protein Therapeutics Forum 2012:1-23, ImmunoGen, Inc., United States (2012).
[cited by applicant]
Polson, A.G., et al., “Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection,”
[cited by applicant]
Press, O.W., et al., “Endocytosis and Degradation of Monoclonal Antibodies Targeting Human B-Cell Malignancies,”
[cited by applicant]
Press, O.W., et al., “Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support,”
[cited by applicant]
Press, O.W., et al., “Retention of B-Cell-Specific Monoclonal Antibodies by Human Lymphoma Cells,”
[cited by applicant]
Press, O.W., et al., “Treatment of Refractory Non-Hodgkin's Lymphoma With Radiolabeled MB-1 (Anti-CD37) Antibody,”
[cited by applicant]
Rops, A.L., et al., “The Tetraspanin CD37 Protects Against Glomerular IgA Deposition and Renal Pathology,”
[cited by applicant]
Schwartz-Albiez, R., et al., “The B Cell-Associated CD37 Antigen (gp40-52): Structure and Subcellular Expression of an Extensively Glycosylated Glycoprotein,”
[cited by applicant]
Sheng, K-C., et al., “Tetraspanins CD37 and CD151 differentially regulate Ag presentation and T-cell co-stimulation by DC,”
[cited by applicant]
Van Spriel, A.B., et al., “A Regulatory Role for CD37 in T Cell Proliferation,”
[cited by applicant]
Van Spriel, A.B., et al., “The Tetraspanin Protein CD37 Regulates IgA Responses and Anti-Fungal Immunity,”
[cited by applicant]
Tedder, T.F., et al., “Structure of the Gene Encoding the Human B Lymphocyte Differentiation Antigen CD20 (B1),”
[cited by applicant]
Zhao, X., et al., “Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical,”
[cited by applicant]
Awan, F., et al., “Phase 1 Study of TRU-016, an Anti-CD37 SMIP Protein in Naïve and Relapsed and/or Refractory CLL Patients,” Poster (2011).
[cited by applicant]
Awan, F.T, et al., “Phase 1 Study of TRU-016, an Anti-CD37 SMIP™ Protein in Naïve and Relapsed and/or Refractory CLL Patients,”
[cited by applicant]
Barrena, S., et al., “Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation,”
[cited by applicant]
Blanc, V., et al., “SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies,”
[cited by applicant]
Heider, K-H., et al., “A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies,”
[cited by applicant]
Lambert, J.M., “Antibody-Maytansinoid Conjugates: A New Strategy for the Treatment of Cancer,”
[cited by applicant]
Pagel, J.M, et al., “Phase 1 Study of TRU-016, An Anti-CD37 SMIP™ Protein in Relapsed and/or Refractory NHL Patients,”
[cited by applicant]
Roguska, M.A., et al., “A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing,”
[cited by applicant]
Roguska, M.A., et al., “Humanization of murine monoclonal antibodies through variable domain resurfacing,”
[cited by applicant]
Teicher, B.A. and Chari, R.V.J., “Antibody Conjugate Therapeutics: Challenges and Potential,”
[cited by applicant]
Dahle, J., et al., “Evaluating Antigen Targeting and Anti-tumor Activity of a New Anti-CD37 Radioimmunoconjugate Against Non-Hodgkin's Lymphoma,”
[cited by applicant]
Lapalombella, R., et al., “Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals,”
[cited by applicant]
Zhao, X.B., et al., “Novel Anti-CD37 Small Modular Immunopharmaceutical (SMP) Induces B-Cell-Specific, Caspase-Independent Apoptosis in Human CLIJ Cells,”
[cited by applicant]
International Search Report and Written Opinion for International Patent Appl. No. PCT/US12/31648 mailed Sep. 20, 2012, Commissioner for Patents, United States.
[cited by applicant]
Preissuance Submission by Third Party under 37 C.F.R. § 1.290, filed in U.S. Appl. No. 13/045,693, filed Mar. 11, 2011.
[cited by applicant]
Kovtun, Y., et al. “Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance,”
[cited by applicant]
Cragg, M.S., et al., “Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts,”
[cited by applicant]
Business Wire, “ImmunoGen, Inc. Announces Presentations at the 102
[cited by applicant]
Beckwith, K.A., et al., “ The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model,”
[cited by applicant]
Yu, B., et al., “Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells,” Biomaterials 34(26):6185-6193, Elsevier Science, Net…
[cited by applicant]
Deckert, J., et al., “A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies,”
[cited by applicant]
Harris, C.L., et al., “Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59,”
[cited by applicant]
Altschuler, E.P., et al., “Method for obtaining recombinant antibodies and for improving affinities thereof”,
[cited by applicant]
Altschuler, E.P., et al., “Generation of Recombinant Antibodies and Means for Increasing Their Affinity,”
[cited by applicant]
Zhao, X., “Targeting CD37 and folate receptor for cancer therapy: strategies based on engineered proteins and liposomes,” Europe PubMed Central, accessed at http://europepmc.org/theses/ETH/6183, accessed on Dec. 9, 2014…
[cited by applicant]
Preissuance Submission by Third Party under 37 C.F.R. § 1.290, filed in U.S. Appl. No. 13/796,768, filed Mar. 12, 2013.
[cited by applicant]
Preissuance Submission by Third Party under 37 C.F.R. § 1.290, filed in U.S. Appl. No. 13/436,528, filed Mar. 30, 2012.
[cited by applicant]
De Pascalis, R., et al., “Grafting of ‘Abbreviated’ Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibo…
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2012/031648, The International Bureau of WIPO, Switzerland, mailed Oct. 2, 2013, pp. 1-9.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2013/034646, Commissioner for Patents, United States, mailed on Sep. 16, 2013, pp. 1-15.
[cited by applicant]
MacCallum, R.M., et al., “Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography,” Journal of Molecular Biology 262(5):732-745, Elsevier, England (1996).
[cited by applicant]
Supplementary European Search Report for Application No. EP11754195, mailed on Sep. 10, 2013, pp. 1-7.
[cited by applicant]
Zhao, X.B., et al., “Novel Anti-CD37 Small Modular Immunopharmaceutical (SMIP) Induces B-Cell-Specific, Caspase-Independent Apoptosis in Human CLL Cells,” Blood 104, Abstract 2515, p. 1 , ASII Annual Meeting, American S…
[cited by applicant]
Zhao Xiaoxian et al: “CD37 Is a Potential Therapeutic Target for B-Cell Non-Hodgkin Lymphoma.”, Blood, 116(21), pp. 1277-1278, American Society of Hematology, United States (Nov. 2011); 52nd Annual Meeting Of The Americ…
[cited by applicant]
Extended European Search Report and written opinion for EP Application No. 13 77 0074, The Hague, The Netherlands, completed on Oct. 20, 2015, pp. 1-9.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US15/30371, Commissioner for Patents, United States, mailed on Nov. 2, 2015, pp. 1-10.
[cited by applicant]
Robak T. et al., “TRU-016, A humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies”, Curr Opin Investig Drugs. 2009. V.10. No. 12, p. 1383-1390, Current Drugs Ltd. England (2009).
[cited by applicant]
Office Action dated Aug. 11, 2015 in Russian Patent Application No. 2012139045/10 (063108), filed Mar. 11, 2011, Applicant: Immunogen, Inc., US.
[cited by applicant]
Morris, G.E., “Epitope Mapping of Protein Antigens by Competition ELISA,”
[cited by applicant]
Marken, J., et al., “Membrane Topology of the L6 Antigen and Identification of the Protein Epitope Recognized by the L6 Monoclonal Antibody,”
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2016/048887, Commissioner for Patents, United States, mailed on Nov. 29, 2016, pp. 1-8.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US16/035558, Commissioner for Patents, United States, mailed on Sep. 7, 2016, pp. 1-11.
[cited by applicant]
Beers, S.A., et al., “Type II (Tositumomab) Anti-CD20 Monoclonal Antibody Out Performs Type I (Rituximab-Like) Reagents in B-Cell Depletion Regardless of Complement Activation,”
[cited by applicant]
Bissery, M., et al., “Experimental Antitumor Activity of Taxotere (RP 56976, NSC 628503), a Taxol Analogue,”
[cited by applicant]
Boross, P. and Leusen, J.H., “Mechanisms of Action of CD20 Antibodies,”
[cited by applicant]
Cheson, B.D., et al., “Revised Response Criteria for Malignant Lymphoma,”
[cited by applicant]
Friedberg, J.W., “Double-Hit Diffuse Large B-cell Lymphoma,”
[cited by applicant]
Green, T.M., et al., “Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients with Diffuse Large B-cell Lymphoma Treated with Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Pred…
[cited by applicant]
Hu, S., et al., “MYC/BCL2 Protein Coexpression Contributes to the Inferior Survival of Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma and Demonstrates High-Risk Gene Expression Signatures: a Report from The I…
[cited by applicant]
Lai, K.C., et al., “Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay,”
[cited by applicant]
Lim, S.H., et al., “Anti-CD20 Monoclonal Antibodies: Historical and Future Perspectives,”
[cited by applicant]
Pers, J.O., et al., “Anti-CD20 Antibody-Mediated Apoptosis of B Cells Is a Lipid Raft-Dependent Process,”
[cited by applicant]
Robak, T. and Robak, E., “New Anti-CD20 Monoclonal Antibodies for the Treatment of B-cell Lymphoid Malignancies,”
[cited by applicant]
Tomayko. M.M. and Reynolds, C.P., “Determination of Subcutaneous Tumor Size in Athymic (Nude) Mice,”
[cited by applicant]
Smith et al., “2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline,”
[cited by applicant]
Romanelli, A., et al., Novel CD37-Targeting Antibody-Drug Conjugate (ADC), IMGN529, Has Synergistic Activity in Combination with Rituximab in Non-Hodgkin Lymphoma (NHL) Models, presented at 13th International Conference…
[cited by applicant]
Deckert, et al., IMGN529, a Novel Antibody-Drug Conjugate (ADC) Targeting CD37 Shows Synergistic Activity with Rituximab in Non-Hodgkin Lymphoma (NHL) Models, poster # 1548, 1 p. 57th ASH Annual Meeting and Exposition, …
[cited by applicant]
Angeletti, R.H., “Design of Useful Peptide Antigens,”
[cited by applicant]
Daniel, C., et al., “Mapping of Linear Antigenic Sites on the S Glycoprotein of a Neurotropic Murine Coronavirus with Synthetic Peptides: A combination of Nine Prediction Algorithms Fails to Identify Relevant Epitopes a…
[cited by applicant]
Greenspan, N.S., et al., “ Defining epitopes: It's not as easy as it seems,”
[cited by applicant]
Gussow, D., et al., “Humanization of Monoclonal Antibodies,”
[cited by applicant]
Lippincott-Schwartz (Current Protocols in Cell Biology) pp. 16.0.1-16.0.2, (2002).
[cited by applicant]
Mariuzza, R.A., et al., “The Structural Basis of Antigen-Antibody Recognition,”
[cited by applicant]
Rudikoff, S., et al., “Single Amino Acid Substitution Altering Antigen-Binding Specificity,”
[cited by applicant]
Office Action mailed Apr. 28, 2017 in U.S. Appl. No. 15/130,667, inventors Deckert, J., et al., filed Apr. 15, 2016, 15 pages.
[cited by applicant]
Office Action mailed Oct. 31, 2017 in U.S. Appl. No. 15/130,667, inventors Deckert, J., et al., filed Apr. 15, 2016, 19 pages.
[cited by applicant]
International Search Report with Written Opinion for International Application No. PCT/IB2017/056841, International Searching Authority, Netherlands, mailed Feb. 2, 2018, 14 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US16/035558, International Search Authority, Switzerland, mailed Dec. 12, 2017, 8 pages.
[cited by applicant]
Stathis, A., et al., “Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation phase I st…
[cited by applicant]
Smith, S.M., et al., “The Impact of MYC expression in lymphoma biology: Beyond Burkitt lymphoma,” Blood Cells, Molecules, and Diseases 45:317-323, Elsevier, Netherlands (2010).
[cited by applicant]
Tedoldi, S., et al., “Selective Loss of B-cell phenotype in lymphocyte predominant Hodgkin lymphoma,” Journal of Pathology 213:429-440, Wiley Interscience, United States (2007).
[cited by applicant]
Office Action mailed May 29, 2018, in U.S. Appl. No. 15/171,732, inventors Romanelli, A.., et al., filed Jun. 2, 2016, 29 pages.
[cited by applicant]
Office 5 mailed Oct. 25, 2017, in U.S. Appl. No. 15/171,732, inventors Romanelli, A.., et al., filed Jun. 2, 2016, 24 pages.
[cited by applicant]
Ackler, S., et al., “The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo,” Cancer Chemother Pharmacol 66(5):869-880, Springer Science+Business Media, Uni…
[cited by applicant]
Alley, S.C., et al., “Antibody-drug conjugates: targeted drug delivery for cancer.” Current Opinion Chem Biol 14:529-537, Elsevier, Netherlands (2010).
[cited by applicant]
Clinical Trials.gov Archive, “NCT01534715; IMGN529 in Treating Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma,” accessed at https://clinicaltrails.gov/archive/NCT01534715/2012_02_16, last accessed Sep. 9, 2…
[cited by applicant]
Deckert, J., et al., “Preclinical Mechanistic Studies Investigating Neutrophil and Lymphoid Cell Depletion by IMGN529, a CD37-Targeting Antibody-Drug Conjugate (ADC),” 56th ASH Annual Meeting and Exposition: Abstract# 3…
[cited by applicant]
Deckert, J., et al., “Preclinical Mechanistic Studies Investigating Neutrophil and Lymphoid Cell Depletion by IMGN529, a CD37-Targeting Antibody-Drug Conjugate (ADC),” 56th ASH Annual Meeting and Exposition: Poster, Abs…
[cited by applicant]
Eugenio, G., et al., Identification of anti-lymphoma biomarkers of response to the anti-cd37 antibody drug conjugate (ADC) IMGN529, presented at 58
[cited by applicant]
Epstein, A.L., et al., “Two New Monoclonal Antibodies, Lym-1 and Lym-2, Reactive With Human B-Lymphocytes and Derived Tumors, with Immunodiagnostic and Immunotherapeutic Potential,” Cancer Research 47:830-840, American …
[cited by applicant]
Hicks, S.W., et al., “The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models,” Neoplasia 19(9):661-671, Elsevier, Netherlands (Sep. 2017).
[cited by applicant]
Konig, A., et al., “Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis,” Leukemia 11:258-265, Nature Publishing Gr…
[cited by applicant]
Rudolph,C., et al., “Molecular Cytogenetic Characterization of the Mantle Cell Lymphoma cell line GRANTA-519,” Cancer Genetics and Cytogenetics 153:144-150, Elsevier, Netherlands (2004).
[cited by applicant]
Sloss, C.M., et al., “IMGN529, a novel Antibody-Drug Conjugate (ADC) targeting CD37, Shows Synergistic Activity with Rituximab in Non-Hodgkin Lymphoma (NHL) Models,” Abstract 1548, presented at American Society of Hemat…
[cited by applicant]
Stathis, A. et al., “Preliminary Findings from a Phase I, Multi-center, Open-label Study of the anti-CD37 Antibody-Drug Conjugate (ADC), IMGN529, in Adult Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NHL),…
[cited by applicant]
Stathis, A. et al., “A Phase I Study Of IMGN529, An Antibody-Drug Conjugate (ADC) Targeting CD37, In Adult Patients With Relapsed Or Refractory Non-Hodgkin Lymphoma (NHL),” 56th ASH Annual Meeting and Exposition: Abstra…
[cited by applicant]
Stathis, A. et al., “A Phase I Study Of IMGN529, An Antibody-Drug Conjugate (ADC) Targeting CD37, In Adult Patients With Relapsed Or Refractory Non-Hodgkin Lymphoma (NHL),” 56th ASH Annual Meeting and Exposition: Poster…
[cited by applicant]
Smolewski, P., et al., “Pro-Apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, of atumumab, on tumor cells from B-cell malignancies,” European Journal of Cancer 50(15):2…
[cited by applicant]
Gross, J., “3333:Evaluation of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR™ Therapeutic in Preclinical Combination Studies with Kinase Inhibitors and a Next Geenration Anti-CD20 Mab in Vitro and in Animal Models of Non…
[cited by applicant]
Gopal, A., et al., “Phase 1b Study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in Combination with Rituximab and Bendamustine in Relapsed Indolent Lymphoma patients,” Investigation…
[cited by applicant]
Algate, P., et al., “TRU-016, An Anti-CD37 SMIP (TM) Biologic, In combination with Other Therapeutic Drugs in Models of Non-Hodgkin's Lymphoma,” Blood 116(21): 1603, Abstract #3931 American Society of Hematology, United…
[cited by applicant]
Deckert, J., et al., “IMGN529, a Novel Antibody-Drug Conjugate (ADC) Targeting CD37 Shows Synergistic Activity with Rituximab in Non-Hodgkin Lymphoma (NHL) Models,” Blood 126(23), 5 pages, American Society of Hematology…
[cited by applicant]
Chen, R., et al., “A Phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma,” Haematologica 100(3):357-362, Ferrata Storti Foundation, Italy (Ma…
[cited by applicant]
Oki, Y., et al., “Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial,” C…
[cited by applicant]
Ducry, L., et al., “Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies,” Bioconjugate 21:5-13, American Chemical Society, United States (2009).
[cited by applicant]
Written Opinion for Singapore Patent Application No. 10201501803Y, dated Sep. 4, 2018, Intellectual Property Office of Singapore, Singapore, 6 pages.
[cited by applicant]
Goel, M., et al., “Plasticity within the Antigen-Combining Site May Manifest as Molecular Mimicry in the Humoral Immune Response,” J. Immunol 173:7358-7367, American Association of immunologists, United States (2004).
[cited by applicant]
Khan, T., et al., “Adjustable Locks and Flexible Keys: Plasticity of Epitope-Paratope Interactions in germline Antibodies,” J Immunol. 192:5398-5405, American Association of immunologists, United States (2014).
[cited by applicant]
Poosarla, V., et al., “Computational De Novo Design of Antibodies Binding to a Peptide with High Affinity,” Biotechnology and Bioengineering 114(6):1331-1342, Wiley Periodicals, United States (2007).
[cited by applicant]
Office action mailed Jul. 2, 2018, U.S. Appl. No. 15/233,423, inventors Deckert, J., et al., filed Aug. 10, 2016, 9 pages.
[cited by applicant]
Epstein, A.L., et al., “Two New Monoclonal Antibodies (LN-1, LN-2) reactive in B5 formalin-fixed paraffin-embedded tissues with follicular center and mantle zone human B lymphocytes and derived tumors.” J. Immunol 133:1…
[cited by applicant]
Awan, F., et al., “Phase 1 Study of TRU-016, an Anti-CD37 SMIP Protein in Naive and Relapsed and/or Refractory CLL Patients,” ASH Annual Meeting 642: Abstract #1792 poster, 1 page, United States (Nov. 2011). Accessed at…
[cited by applicant]
Co, M.S., et al., “Chimeric and Humanized Antibodies With Specificity for the CD33 Antigen,” Journal of immunology 148(4):1149-1154., American Association of Immunologists, United States (Feb. 1992).
[cited by applicant]
Colman, P.M., “Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions,” Research in Immunology 145(1):33-36, Elsevier, France (Jan. 1994).
[cited by applicant]
Deckert, J., et al., “IMGN529, a Novel Antibody-Drug Conjugate (ADC) Targeting CD37 Shows Synergistic Activity with Rituximab in Non-Hodgkin Lymphoma (NHL) Models,” Blood 126(23):1548, Abstract, 4 pages, American Societ…
[cited by applicant]
Deckert, et al., “Preclinical Mechanistic Studies Investigating Neutrophil and Lymphoid Cell Depletion by IMGN529, a CD37-Targeting Antibody-Drug Conjugate (ADC),” Abstract # 3119, 2 pages, 57th ASH Annual Meeting and E…
[cited by applicant]
Deckert, J., et al., “IMGN529, a Novel Antibody-Drug Conjugate (ADC) Targeting CD37 Shows Synergistic Activity with Rituximab in Non-Hodgkin Lymphoma (NHL) Models,” Blood 126(23):1548, poster, 1 page, American Society o…
[cited by applicant]
Gershoni, J.M., et al., “Epitope Mapping: the First Step in Developing Epitope-based Vaccines,” BioDrugs 21(3):145-156, Springer International, New Zealand (2007).
[cited by applicant]
Lai, K.C., et al., “The CD37-targeting ADC IMGN529 Combines the Potent Anti-cancer Activity of K7153A Antibody with Efficient Maytansinoid Delivery,” American Association for Cancer Research Hosted by the European Organ…
[cited by applicant]
Paul, W.E., “Immunogenicity and Antigen Structure,” in Fundamental Immunology, Third Edition, pp. 242, Raven Press, United States (1993).
[cited by applicant]
Tutt, A., et al., “Trispecific F(ab′)
[cited by applicant]
Wang, L., et al., “Structural Characterization of the Maytansinoid-Monoclonal Antibody Immunoconjugate, huN901-DM1, by mass spectrometry, ” Protein Science, 14(9):2436-2446, Cold Spring Harbor Laboratory Press, United S…
[cited by applicant]
Wang, Z., et al., “Universal PCR Amplification of Mouse Immunoglobulin Gene Variable Regions: the Design of Degenerate Primers and an Assessment of the Effect of DNA Polymerase 3′ to 5′ Exonuclease Activity,” Journal of…
[cited by applicant]
Zenz, T., et al., “Exceptional In Vitro Activity of CD37 Antibodies in CLL,” Blood 116(21):1021-1022, 2010 ASH Annual Meeting Abstracts (Abstract 2460), American Society of Hematology, United States (2010), accessed at …
[cited by applicant]
Zhao, X., et al., “CD37 is a Potential Therapeutic Target for B-Cell Non-Hodgkin Lymphoma,” Blood, 116(21), Abstract #3098, p. 1, American Society of Hematology, United States (Nov. 2011); 52nd Annual Meeting of the Ame…
[cited by applicant]
Zhao, X., “Targeting CD37 and folate receptor for cancer therapy: strategies based on engineered proteins and liposomes,” Ohio Link Electronic Theses & Dissertations Center, document No. osul 174678307, pp. 1-314, The O…
[cited by applicant]
Heppner, G.H., et al., “Tumor heterogeneity: biological implications and therapeutic consequences,” Cancer Metastasis Rev. 2(1):5-23, Martinus Nihoff Publishers, Netherlands (1983).
[cited by applicant]
Jain, R.K., “Barriers to Drug Delivery in Solid Tumors,” Scientific American 271(1):58-65, Scientific American Inc, United States (1994).
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2016/048887, International Searching Authority, United States, mailed Nov. 29, 2016, 5 pages.
[cited by applicant]
Barthelemy P.A., et al., “Comprehensive Analysis of the Factors Contributing to the Stability and Solubility of Autonomous Human VH Domains,” The Journal of Biological Chemistry 283, 3639-3654, American Society for Bioc…
[cited by applicant]
Beiboer, S.H., et al., “Guided Selection of a Pan Carcinoma Specific Antibody Reveals Similar Binding Characteristics yet Structural Divergence between the Original Murine Antibody and its Human Equivalent,” Journal of …
[cited by applicant]
Choi Y, and Deane C.M., “Predicting Antibody Complementarity Determining Region Structures Without Classification,” Molecular BioSystems 7:3327-3334, The Royal Society of Chemistry (Sep. 2011).
[cited by applicant]
De Genst, E., et al., “Antibody Repertoire Development in Camelids,” Developmental and Comparative Immunology 30(1-2):187-198, Elsevier Science, United States (2006).
[cited by applicant]
Griffiths, A.D., et al., “Human Anti-Self Antibodies with High Specificity from Phage Display Libraries,” The EMBO Journal 12(2):725-734, Wiley Blackwell, England (Feb. 1993).
[cited by applicant]
International Search Report and Written Opinion mailed Aug. 21, 2019, in International Application No. PCT/IB2019/054457, EPO, Netherlands, 11 pages.
[cited by applicant]
Klimka, A., et al., “Human Anti-CD30 Recombinant Antibodies by Guided Phage Antibody Selection Using Cell Panning,” British Journal of Cancer 83(2):252-260, Nature Publishing Group, England (Jul. 2000).
[cited by applicant]
Levy, M. Y., et al., “Safety and efficacy of CD37-Targeting Naratuximab Emtansine plus Rituximab in Diffuse Large B-cell Lymphoma and Other Non-Hodgkin's B-cell Lymphomas—a Phase 2 Study,” Poster #244, presented at the …
[cited by applicant]
Malia, T.J., et al., “Epitope Mapping and Structural Basis for the Recognition of Phosphory lated Tau by the Anti-tau Antibody AT8,” Proteins 84(4):427-434, Wiley-Liss, United States (Apr. 2016).
[cited by applicant]
Ward, E.S., et al., “Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from
[cited by applicant]
Prescribing Information, “Rituxan,” retrieved from: https://www.gene.com/download/pdf/rituxan_prescribing.pdf, 53 pages. Initial U.S. Approval: 1997. Last updated Jun. 2021.
[cited by applicant]
Office action mailed Aug. 3, 2021, in U.S. Appl. No. 16/221,747, inventors Deckert, et al., filed Dec. 17, 2018, 13 pages.
[cited by applicant]
Office action mailed May 16, 2018, in U.S. Appl. No. 15/130,667, inventors Deckert, et al., filed Apr. 15, 2016, 6 pages.
[cited by applicant]
Office action mailed Sep. 3, 2015, in U.S. Appl. No. 13/796,768, inventors Deckert, et al., filed Mar. 12, 2013, 11 pages.
[cited by applicant]
Office action mailed Dec. 11, 2015, in U.S. Appl. No. 13/796,768, inventors Deckert, et al., filed Mar. 12, 2013, 8 pages.
[cited by applicant]
Co-pending Application, U.S. Appl. No. 17/938,886, inventors Deckert, J., et al., filed Oct. 7, 2022 (Not Published).
[cited by applicant]